Print
.gif)
- Cephalon Board Rejects Valeant’s Unsolicited $5.7 Billion Bid As Too Low
Reuters - Mouse Stem-Cell Discovery May Lead to Blindness Therapies, Researchers Say
Bloomberg - Drugs’ Cost and Safety Fuel a Fight
The New York Times - G.O.P. Blueprint Would Remake Health Policy
The New York Times - Senate Passes Change to Health Law
The New York Times - Valeant Pharma Offers to Acquire Cephalon for $5.7 Billion
Bloomberg - Bayer plans to raise BRIC revenue to 10 bln-paper
Reuters - States Weigh Fighting Meth With Drug Prescriptions
The New York Times - Protalix Plans Human Clinical Tests of Medication for Rare Fabry's Disease
Bloomberg - Branded drug prices soar as generic pressure rises
Reuters